Published in Oncoimmunology on September 01, 2012
MicroRNA-mediated down-regulation of NKG2D ligands contributes to glioma immune escape. Oncotarget (2014) 1.09
Effective immuno-targeting of the IDH1 mutation R132H in a murine model of intracranial glioma. Acta Neuropathol Commun (2015) 0.84
A role for intracellular zinc in glioma alteration of neuronal chloride equilibrium. Cell Death Dis (2014) 0.80
Recent advances and future of immunotherapy for glioblastoma. Expert Opin Biol Ther (2016) 0.77
The multidrug-resistance transporter Abcc3 protects NK cells from chemotherapy in a murine model of malignant glioma. Oncoimmunology (2015) 0.75
Advances in Immunotherapy for Glioblastoma Multiforme. J Immunol Res (2017) 0.75
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med (2005) 74.55
Identification of human brain tumour initiating cells. Nature (2004) 38.87
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol (2009) 25.96
Identification of a cancer stem cell in human brain tumors. Cancer Res (2003) 24.02
Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells. Science (1995) 17.42
Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science (2011) 15.79
Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res (2004) 14.73
Selective attraction of monocytes and T lymphocytes of the memory phenotype by cytokine RANTES. Nature (1990) 7.15
Immunological aspects of cancer chemotherapy. Nat Rev Immunol (2008) 6.61
Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. J Clin Oncol (2010) 6.30
Radial glia give rise to adult neural stem cells in the subventricular zone. Proc Natl Acad Sci U S A (2004) 3.91
The secret ally: immunostimulation by anticancer drugs. Nat Rev Drug Discov (2012) 3.60
Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment. Clin Cancer Res (2005) 3.35
The basic leucine zipper transcription factor E4BP4 is essential for natural killer cell development. Nat Immunol (2009) 3.27
Cytokine RANTES released by thrombin-stimulated platelets is a potent attractant for human eosinophils. J Exp Med (1992) 3.20
Alpha and beta chemokines induce NK cell migration and enhance NK-mediated cytolysis. J Immunol (1995) 2.52
Vaccination elicits correlated immune and clinical responses in glioblastoma multiforme patients. Cancer Res (2008) 2.12
Postoperative adjuvant dendritic cell-based immunotherapy in patients with relapsed glioblastoma multiforme. Clin Cancer Res (2008) 2.04
Neurospheres enriched in cancer stem-like cells are highly effective in eliciting a dendritic cell-mediated immune response against malignant gliomas. Cancer Res (2006) 1.89
RNA interference targeting transforming growth factor-beta enhances NKG2D-mediated antiglioma immune response, inhibits glioma cell migration and invasiveness, and abrogates tumorigenicity in vivo. Cancer Res (2004) 1.83
C-C chemokines, but not the C-X-C chemokines interleukin-8 and interferon-gamma inducible protein-10, stimulate transendothelial chemotaxis of T lymphocytes. Eur J Immunol (1995) 1.80
Clinical evaluation of dendritic cell vaccination for patients with recurrent glioma: results of a clinical phase I/II trial. Clin Cancer Res (2005) 1.76
Homing phenotypes of tumor-specific CD8 T cells are predetermined at the tumor site by crosspresenting APCs. Immunity (2005) 1.74
Preferential migration of regulatory T cells mediated by glioma-secreted chemokines can be blocked with chemotherapy. Cancer Immunol Immunother (2007) 1.70
An [Na+ + K+]coupled L-glutamate transporter purified from rat brain is located in glial cell processes. Neuroscience (1992) 1.70
Beta chemokines costimulate lymphocyte cytolysis, proliferation, and lymphokine production. J Leukoc Biol (1996) 1.70
An epidermal growth factor receptor variant III-targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme. Mol Cancer Ther (2009) 1.67
Toll like receptor-3 ligand poly-ICLC promotes the efficacy of peripheral vaccinations with tumor antigen-derived peptide epitopes in murine CNS tumor models. J Transl Med (2007) 1.64
TGF-beta and metalloproteinases differentially suppress NKG2D ligand surface expression on malignant glioma cells. Brain (2006) 1.54
Vaccination of glioma patients with fusions of dendritic and glioma cells and recombinant human interleukin 12. J Immunother (2004) 1.48
NK cells recognize and kill human glioblastoma cells with stem cell-like properties. J Immunol (2009) 1.46
TGF-beta downregulates the activating receptor NKG2D on NK cells and CD8+ T cells in glioma patients. Neuro Oncol (2009) 1.43
Immunobiological characterization of cancer stem cells isolated from glioblastoma patients. Clin Cancer Res (2010) 1.37
Opposing effects of toll-like receptor (TLR3) signaling in tumors can be therapeutically uncoupled to optimize the anticancer efficacy of TLR3 ligands. Cancer Res (2010) 1.31
Migration of human blood dendritic cells across endothelial cell monolayers: adhesion molecules and chemokines involved in subset-specific transmigration. J Leukoc Biol (2003) 1.22
Preferential expression of very late antigen-4 on type 1 CTL cells plays a critical role in trafficking into central nervous system tumors. Cancer Res (2007) 1.22
Autologous glioma cell vaccine admixed with interleukin-4 gene transfected fibroblasts in the treatment of recurrent glioblastoma: preliminary observations in a patient with a favorable response to therapy. J Neurooncol (2003) 1.16
Autologous glioma cell vaccine admixed with interleukin-4 gene transfected fibroblasts in the treatment of patients with malignant gliomas. J Transl Med (2007) 1.15
Immunological basis of the development of necrotic lesions following Mycobacterium avium infection. Immunology (2002) 1.09
Genetic alterations and in vivo tumorigenicity of neurospheres derived from an adult glioblastoma. Mol Cancer (2004) 1.06
RANTES activates antigen-specific cytotoxic T lymphocytes in a mitogen-like manner through cell surface aggregation. Int Immunol (2000) 1.03
Human glioblastoma stem-like cells are more sensitive to allogeneic NK and T cell-mediated killing compared with serum-cultured glioblastoma cells. Brain Pathol (2011) 1.02
Cutting edge: RANTES regulates Fas ligand expression and killing by HIV-specific CD8 cytotoxic T cells. J Immunol (1999) 0.86
Brain cancer immunoediting: novel examples provided by immunotherapy of malignant gliomas. Expert Rev Anticancer Ther (2011) 0.84
Cloning and characterization of a glutamate transporter cDNA from human cerebellum. Biochim Biophys Acta (1993) 0.80
RANTES is a pro-inflammatory chemokine and chemoattracts basophil cells to extravascular sites. J Pathol (1997) 0.80
The somatic genomic landscape of glioblastoma. Cell (2013) 11.73
Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. N Engl J Med (2015) 5.71
Transforming fusions of FGFR and TACC genes in human glioblastoma. Science (2012) 5.09
The integrated landscape of driver genomic alterations in glioblastoma. Nat Genet (2013) 2.89
Human circulating AC133(+) stem cells restore dystrophin expression and ameliorate function in dystrophic skeletal muscle. J Clin Invest (2004) 2.00
Identification of tumor-specific molecular signatures in intracranial ependymoma and association with clinical characteristics. J Clin Oncol (2006) 1.92
Neurospheres enriched in cancer stem-like cells are highly effective in eliciting a dendritic cell-mediated immune response against malignant gliomas. Cancer Res (2006) 1.89
Prognostic factors for survival in 676 consecutive patients with newly diagnosed primary glioblastoma. Neuro Oncol (2007) 1.59
High-resolution genomic copy number profiling of glioblastoma multiforme by single nucleotide polymorphism DNA microarray. Mol Cancer Res (2009) 1.53
Human skin-derived stem cells migrate throughout forebrain and differentiate into astrocytes after injection into adult mouse brain. J Neurosci Res (2004) 1.33
The MET oncogene is a functional marker of a glioblastoma stem cell subtype. Cancer Res (2012) 1.21
Methylation of O6-methylguanine DNA methyltransferase and loss of heterozygosity on 19q and/or 17p are overlapping features of secondary glioblastomas with prolonged survival. Clin Cancer Res (2007) 1.19
A role for the transcription factor HEY1 in glioblastoma. J Cell Mol Med (2008) 1.16
NEDD9, a novel target of miR-145, increases the invasiveness of glioblastoma. Oncotarget (2012) 1.15
Intra-tumoral dendritic cells increase efficacy of peripheral vaccination by modulation of glioma microenvironment. Neuro Oncol (2010) 1.13
Expression of the neurogenic basic helix-loop-helix transcription factor NEUROG1 identifies a subgroup of medulloblastomas not expressing ATOH1. Neuro Oncol (2007) 1.10
The therapeutic potential of neural stem/progenitor cells in murine globoid cell leukodystrophy is conditioned by macrophage/microglia activation. Neurobiol Dis (2005) 1.08
Genetic alterations and in vivo tumorigenicity of neurospheres derived from an adult glioblastoma. Mol Cancer (2004) 1.06
Expression of MATH1, a marker of cerebellar granule cell progenitors, identifies different medulloblastoma sub-types. Neurosci Lett (2004) 1.05
Sox2 is required to maintain cancer stem cells in a mouse model of high-grade oligodendroglioma. Cancer Res (2014) 1.00
Different simian virus 40 genomic regions and sequences homologous with SV40 large T antigen in DNA of human brain and bone tumors and of leukocytes from blood donors. Cancer (2002) 1.00
Survival effect of first- and second-line treatments for patients with primary glioblastoma: a cohort study from a prospective registry, 1997-2010. Neuro Oncol (2014) 0.99
The Integrated Oncology Program of the Italian Ministry of Health. Analytical and clinical validation of new biomarkers for early diagnosis: network, resources, methodology, quality control, and data analysis. Int J Biol Markers (2009) 0.93
Identification of a putative pathway for the muscle homing of stem cells in a muscular dystrophy model. J Cell Biol (2003) 0.92
DNA damage in mammalian neural stem cells leads to astrocytic differentiation mediated by BMP2 signaling through JAK-STAT. Stem Cell Reports (2013) 0.91
A radial glia gene marker, fatty acid binding protein 7 (FABP7), is involved in proliferation and invasion of glioblastoma cells. PLoS One (2012) 0.91
Association of chromosome 10 losses and negative prognosis in oligoastrocytomas. Ann Neurol (2002) 0.91
FOXP3, a novel glioblastoma oncosuppressor, affects proliferation and migration. Oncotarget (2012) 0.90
Prognostic value of CD109+ circulating endothelial cells in recurrent glioblastomas treated with bevacizumab and irinotecan. PLoS One (2013) 0.89
A critical role for regulatory T cells in driving cytokine profiles of Th17 cells and their modulation of glioma microenvironment. Cancer Immunol Immunother (2011) 0.89
Reelin affects chain-migration and differentiation of neural precursor cells. Mol Cell Neurosci (2009) 0.89
Extraneural metastases in glioblastoma patients: two cases with YKL-40-positive glioblastomas and a meta-analysis of the literature. Neurosurg Rev (2015) 0.89
MGMT promoter hypermethylation in a series of 104 glioblastomas. Cancer Genomics Proteomics (2009) 0.88
Immunotherapy for glioma: getting closer to the clinical arena? Curr Opin Neurol (2011) 0.88
FABP4 is a candidate marker of cerebellar liponeurocytomas. J Neurooncol (2012) 0.86
Reclassification of oligoastrocytomas by loss of heterozygosity studies. Int J Cancer (2006) 0.86
DNA microarray analysis identifies CKS2 and LEPR as potential markers of meningioma recurrence. Oncologist (2011) 0.85
The neural progenitor-restricted isoform of the MARK4 gene in 19q13.2 is upregulated in human gliomas and overexpressed in a subset of glioblastoma cell lines. Oncogene (2003) 0.85
The natural killer cell response and tumor debulking are associated with prolonged survival in recurrent glioblastoma patients receiving dendritic cells loaded with autologous tumor lysates. Oncoimmunology (2013) 0.84
Brain cancer immunoediting: novel examples provided by immunotherapy of malignant gliomas. Expert Rev Anticancer Ther (2011) 0.84
Effective immuno-targeting of the IDH1 mutation R132H in a murine model of intracranial glioma. Acta Neuropathol Commun (2015) 0.84
KLF6 is not the major target of chromosome 10p losses in glioblastomas. Int J Cancer (2004) 0.83
Rai is a new regulator of neural progenitor migration and glioblastoma invasion. Stem Cells (2012) 0.83
Instability of mitochondrial DNA and MRI and clinical correlations in malignant gliomas. J Neurooncol (2005) 0.82
Perspectives for immunotherapy in glioblastoma treatment. Curr Opin Oncol (2014) 0.82
An optimized method for manufacturing a clinical scale dendritic cell-based vaccine for the treatment of glioblastoma. PLoS One (2012) 0.81
Dendritic cell vaccines for cancer stem cells. Methods Mol Biol (2009) 0.80
Genetic signature of adult gliomas and correlation with MRI features. Expert Rev Mol Diagn (2009) 0.80
Brain engraftment and therapeutic potential of stem/progenitor cells derived from mouse skin. J Gene Med (2006) 0.79
Erratum to: Extraneural metastases in glioblastoma patients: two cases with YKL-40-positive glioblastomas and a meta-analysis of the literature. Neurosurg Rev (2015) 0.79
Novel mechanisms and approaches in immunotherapy for brain tumors. Discov Med (2015) 0.78
Expression studies in gliomas and glial cells do not support a tumor suppressor role for LGI1. Neuro Oncol (2006) 0.78
VEGFA SNP rs2010963 is associated with vascular toxicity in recurrent glioblastomas and longer response to bevacizumab. J Neurooncol (2014) 0.78
Frequency of NFKBIA deletions is low in glioblastomas and skewed in glioblastoma neurospheres. Mol Cancer (2013) 0.77
Radiation-induced glioblastoma in a medulloblastoma patient: a case report with molecular features. Neuropathology (2008) 0.77
Operability of glioblastomas: "sins of action" versus "sins of non-action". Neurol Sci (2013) 0.77
Alternative sources of neurons and glia from somatic stem cells. Cell Transplant (2002) 0.77
Salvage treatment for childhood ependymoma after surgery only: Pitfalls of omitting "at once" adjuvant treatment. Int J Radiat Oncol Biol Phys (2006) 0.76
From standard treatment to personalized medicine: role of IDH1 mutations in low-grade glioma evolution and treatment. World Neurosurg (2010) 0.76
Radiosurgery reirradiation for high-grade glioma recurrence: a retrospective analysis. Neurol Sci (2015) 0.76
The potential of stem cells for the treatment of brain tumors and globoid cell leukodystrophy. Cytotechnology (2003) 0.75
Expression of parathyroid-specific genes in vascular endothelial progenitors of normal and tumoral parathyroid glands. Am J Pathol (2009) 0.75
Central nervous system lymphoma occurring in a patient with neurofibromatosis type 1 (von Recklinghausen disease). Neurol Sci (2012) 0.75
Expression profile of frizzled receptors in human medulloblastomas. J Neurooncol (2011) 0.75
Loss of heterozygosity studies in extracranial metastatic meningiomas. J Neurooncol (2007) 0.75
Erratum to: Radiosurgery reirradiation for high-grade glioma recurrence: a retrospective analysis. Neurol Sci (2015) 0.75